NCT02312050View on ClinicalTrials.gov

A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

PHASE2UnknownINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

December 31, 2016

Conditions
Diabetic Chronic Kidney Disease
Interventions
DRUG

GCS-100

1 mg, 3 mg, or 9 mg IV push injections

DRUG

Placebo

Trial Locations (8)

28801

Mountain Kidney & Hypertension, Asheville

37408

Southeast Renal Research Institute, Chattanooga

78215

Clinical Advancement Center, San Antonio

80230

Denver Nephrology, Denver

91910

Balboa Nephrology Medical Group, Chula Vista

91942

California Institute for Renal Research, La Mesa

92037

Balboa Nephrology Medical Group, La Jolla

92243

Balboa Nephrology Medical Group, El Centro

Sponsors
All Listed Sponsors
lead

La Jolla Pharmaceutical Company

INDUSTRY

NCT02312050 - A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes | Biotech Hunter | Biotech Hunter